- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03187795
Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury (MOSET-SCI)
Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Neurogenic detrusor overactivity or "NDO" is common in people with spinal cord injury (SCI) and is a medical condition characterized by involuntary urinary bladder contractions. These bladder contractions can cause episodes of urinary incontinence (involuntary urine leakage) and/or high bladder pressures that can lead to poor drainage from the kidneys and urinary tract infections (UTIs).
Neurogenic detrusor overactivity is most commonly treated with a medication called oxybutynin (Ditropan); however, this medication is associated with side effects such as dry mouth and constipation. Mirabegron (Myrbetriq) is a newer medication approved by the Food and Drug Administration for the treatment of overactive bladder that does not cause dry mouth or constipation; however, its use in persons with SCI is investigational.
The purpose of this research study is to determine the effectiveness and safety of mirabegron compared to oxybutynin chloride immediate release (oxybutynin IR) for neurogenic detrusor overactivity in individuals with SCI.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
West Orange, New Jersey, United States, 07052
- Recruiting
- Kessler Institute for Rehabilitation
-
Contact:
- Trevor A. Dyson-Hudson, M.D.
- Phone Number: 973-324-3576
- Email: tdysonhudson@kesslerfoundation.org
-
Principal Investigator:
- Steven C. Kirshblum, M.D.
-
Contact:
- Todd A. Linsenmeyer, M.D.
- Phone Number: 973-243-6924
- Email: tlinsenmeyer@kessler-rehab.com
-
Principal Investigator:
- Todd A. Linsenmeyer, M.D.
-
Principal Investigator:
- Trevor A. Dyson-Hudson, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject has a neurological impairment secondary to a traumatic spinal cord injury that occurred at least twelve (12) months prior to the screening visit.
- The injury is classified as complete or incomplete (AIS grade A-D) and the neurological level of the injury is above T12.
- The subject's method of bladder management is intermittent catheterization (IC) or indwelling catheter (transurethral or suprapubic).
- There is urodynamic documentation of neurogenic detrusor overactivity (NDO).
- The subject is on a stable dose of oxybutynin IR three times daily.
- The subject is able and willing to comply with the study protocol, including availability for all scheduled clinic visits and locomotor training sessions.
- The subject is able to and has voluntarily given informed consent prior to the performance of any study-specific procedures.
Exclusion Criteria:
- The subject has taken mirabegron within one month of the Screening Visit.
- The subject has received a botulinum toxin injection to the bladder within one year of the Screening Visit.
- The subject is allergic to mirabegron.
- The subject has a history of uncontrolled autonomic dysreflexia or significant autonomic dysreflexia on urodynamics (systolic BP≥150 mm/Hg).
- The subject has a known history of significant anatomical problems of the upper tracts, including hydronephrosis, kidney stones, or ureteropelvic junction obstruction.
- The subject has a known history or treatment for a non-neurogenic bladder or prostate problem (prostate cancer, bladder cancer).
- The subject has recurrent UTIs, defined as a UTI more than every three months.
- The subject has untreated Grade 3 or above vesicoureteral reflux.
- If female, the subject is pregnant (documented by a urine pregnancy test) or breastfeeding.
- The subject has taken another investigational drug within 30 days before screening.
- The subject has a medical condition that might pose a safety issue or would interfere with interpretation of study results or study conduct.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oxybutynin chloride IR then Mirabegron
Subjects randomized to this group will receive oxybutynin IR (5 mg three times daily) for 6 weeks.
After the initial 6 weeks, subjects in this group will then be switched to an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
|
Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
Other Names:
Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
Other Names:
|
Experimental: Mirabegron then Oxybutynin chloride IR
Subjects randomized to this group will receive an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
After the initial 6 weeks, subjects in this group will then be switched to receive oxybutynin IR (5 mg three times daily) for 6 weeks
|
Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
Other Names:
Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cystometric bladder capacity during filing cystometry
Time Frame: Week 6 and Week 12
|
The cystometric bladder capacity is the bladder volume (ml) at the end of the filling cystometrogram, when 'permission to void' is usually given.
|
Week 6 and Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in detrusor leak point pressure
Time Frame: Week 6 and Week 12
|
The detrusor leak point pressure (cm H2O) is defined as the lowest detrusor pressure at which urine leakage occurs in the absence of either a detrusor contraction or increased abdominal pressure.
|
Week 6 and Week 12
|
Change in maximum detrusor pressure
Time Frame: Week 6 and Week 12
|
Maximum detrusor pressure (ml/cm H2O) as the name implies, is the maximum detrusor pressure during filling cystometry.
|
Week 6 and Week 12
|
Change in bladder compliance during filling cystometry
Time Frame: Week 6 and Week 12
|
Bladder compliance during filling cystometry (ml/cm H2O) is the relationship between change in bladder volume and change in detrusor pressure and is calculated by dividing the volume change (ΔV) by the change in detrusor pressure (Δρdet) during that change in bladder volume (C= ΔV/Δρdet).
|
Week 6 and Week 12
|
Change in post-void residual volume
Time Frame: Week 6 and Week 12
|
The post-void residual volume (ml) is defined as the volume of urine left in the bladder at the end of micturition1 and is recommended as a core urodynamic outcome measure in SCI.
|
Week 6 and Week 12
|
Change on International Lower Urinary Tract Function Basic Spinal Cord Injury (SCI) Data Set
Time Frame: Week 6 and Week 12
|
The purpose of the Lower Urinary Tract Function Basic Data Set for Spinal Cord Injury (SCI) individuals is to standardize the collection and reporting of information on the lower urinary tract and to make it possible to evaluate and compare results from various published studies.
|
Week 6 and Week 12
|
Change on Bowel Function Measures - International SCI Bowel Function Basic & Extended Data Sets
Time Frame: Week 6 and Week 12
|
The International Bowel Function Basic and Extended SCI Data Sets present a standardized format for the collection and reporting of an extended amount of information on bowel function in persons with SCI.
|
Week 6 and Week 12
|
Change in California Verbal Learning Test - II (CVLT) scores
Time Frame: Week 6 and Week 12
|
Memory will be assessed by the California Verbal Learning Test - II (CVLT).
It consists of a list of 16 words from 4 semantic categories presented orally over 5 trials and includes a 20 minute delayed recall trial as well as a recognition trial.
|
Week 6 and Week 12
|
Change in Symbol Digit Modalities Test oral version (SDMT) scores
Time Frame: Week 6 and Week 12
|
Processing speed will be assessed by the Symbol Digit Modalities Test oral version.
|
Week 6 and Week 12
|
Wechsler Test of Adult Reading (WTAR) score
Time Frame: Screening Visit
|
The Wechsler Test of Adult Reading will be administered to provide an estimate of verbal intelligence for later use as a covariate in the analyses of the cognitive outcomes.
The WTAR is composed of 50 irregularly spelled words and takes approximately 10 minutes to complete.
|
Screening Visit
|
Change in Qualiveen scores
Time Frame: Week 6 and Week 12
|
The Qualiveen was developed as a condition-specific QOL measure for individuals with SCI.
It consists of 30 items focusing on four aspects of individuals' lives related to their urinary problems: bother with limitations, frequency of limitations, fears, and feelings.
|
Week 6 and Week 12
|
Change in SCI-QOL Bowel & Bladder Management Difficulties scores
Time Frame: Week 6 and Week 12
|
The SCI-QOL Bladder Management Difficulties and SCI-QOL Bowel Management Difficulties were developed as QOL measure for individuals with SCI and are part of the SCI-QOL measurement system.
|
Week 6 and Week 12
|
Change in Subject Global Impression (SGI) of Change score
Time Frame: Week 6 and Week 12
|
The SGI of change is a subject-rated instrument that measures change in the subject's overall status on a 7-point scale.
|
Week 6 and Week 12
|
Change in Clinician Global Impression (CGI) of Change score
Time Frame: Week 6 and Week 12
|
The study physician will rate on a 7-point scale the subject's overall clinical condition following treatment as compared to that at baseline.
|
Week 6 and Week 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event Case Report Form
Time Frame: Every two weeks for 12 weeks
|
Adverse experience(s) will be recorded on the Adverse Event Case Report Form, including the date and time of onset, severity, the relationship to study intervention, the date of resolution, the action taken, and the outcome of the adverse experience.
The responsible physician will make a causality assessment for every adverse experience.
|
Every two weeks for 12 weeks
|
Side Effects Record
Time Frame: Every two weeks for 12 weeks
|
Participants will be provided a list of side-effects associated with oxybutynin and mirabegron treatment.
Three lines marked "other" for open-choice responses will accompany the selection of options for forced-choice side-effects.
Participants will rate the severity (visual analog scale (VAS); 0-100) and frequency ("never", "occasionally", "sometimes", "often" or "always") of side effects for each of the forced and open choice answers.
Severity and frequency of side-effects will be rated by participants every 2 weeks during the intervention part of the study.
|
Every two weeks for 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven C. Kirshblum, M.D., Kessler Institute for Rehabilitation
- Principal Investigator: Trevor A. Dyson-Hudson, M.D., Kessler Foundation
- Principal Investigator: Todd A. Linsenmeyer, M.D., Kessler Institute for Rehabilitation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Urologic Diseases
- Urinary Bladder Diseases
- Neurologic Manifestations
- Trauma, Nervous System
- Spinal Cord Diseases
- Wounds and Injuries
- Spinal Cord Injuries
- Urinary Bladder, Neurogenic
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Adrenergic Agonists
- Adrenergic beta-Agonists
- Adrenergic beta-3 Receptor Agonists
- Oxybutynin
- Mirabegron
Other Study ID Numbers
- D-961-17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injuries
-
Khon Kaen UniversityUnknownInjuries, Spinal Cord
-
Universidade do Vale do ParaíbaCompletedInjuries, Spinal Cord
-
Ekso BionicsBurke Medical Research InstituteCompletedInjuries, Spinal CordUnited States
-
ReWalk Robotics, Inc.Unknown
-
InVivo TherapeuticsTerminated
-
Shepherd Center, Atlanta GACompletedInjuries, Spinal Cord
-
Wroclaw Medical UniversityInstitute of Immunology and Experimental Therapy of the Polish Academy of... and other collaboratorsUnknownComplete Spinal Cord InjuriesPoland
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Epidural Spinal Cord CompressionUnited States
Clinical Trials on Oxybutynin Chloride IR
-
AllerganCompletedOveractive BladderUnited States
-
Watson PharmaceuticalsCompletedHealthy VolunteersUnited States
-
Ortho-McNeil Janssen Scientific Affairs, LLCCompleted
-
Alza Corporation, DE, USACompleted
-
Janssen Korea, Ltd., KoreaCompleted
-
McNeil Consumer & Specialty Pharmaceuticals, a...Completed
-
Watson PharmaceuticalsCompleted
-
US Department of Veterans AffairsCompleted
-
Bioxodes S.A.Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingProstate CarcinomaUnited States